|
|
|
02.12.25 - 22:45
|
New Data Presented at the Clinical Trials on Alzheimer′s Disease (CTAD) Conference 2025 Confirms Pharmacological Effect of LEQEMBI® (lecanemab-irmb) on Neurotoxic Aβ Protofibrils in CSF (PR Newswire)
|
|
|
TOKYO and CAMBRIDGE, Mass., Dec. 2, 2025 /PRNewswire/ -- Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, "Eisai") and Biogen Inc. (Nasdaq: BIIB, Corporate headquarters: Cambridge, Massachusetts, CEO: Christopher A. Viehbacher, "Biogen") announced today that the latest data......
|
|
|
|
|
|
|
01.12.25 - 13:36
|
Stoke Therapeutics and Biogen Announce Presentations at the 2025 American Epilepsy Society Annual Meeting (Business Wire)
|
|
|
– New analyses from the ongoing open label extension (OLE) studies and findings from electroencephalogram (EEG) assessments in patients with Dravet syndrome treated with zorevunersen support the potential for disease modification –
BEDFORD, Mass. & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Stoke Therapeutics, Inc. (Nasdaq: STOK), a biotechnology company dedicated to restoring protein expression by harnessing the body's potential with RNA medicine, and Biogen Inc. (Nasdaq: BIIB) today announced data presentations from studies of zorevunersen at the 2025 American Epilepsy Society (AES) Annual Meeting, taking place December 5-9 in Atlanta, Georgia.
Zorevunersen is an investigational antisense oligonucleotide currently being evaluated as a potential first-in-class medicine for the treatment of Dravet syndrome, a severe developmental and epileptic encephalopathy (DEE) characterized by recurrent seizures and significant cognitive and behavioral impairments. Data to be presented at AES are derived from four years ...
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
24.11.25 - 13:36
|
Versant Ventures Announces Launch of Dayra Therapeutics With Foundational Biogen Partnership (Business Wire)
|
|
|
- Startup emerges from Versant's Frontier Discovery Engine with over $70 million in capital to develop oral macrocyclic peptides
- Biogen and Dayra partnership will identify, validate and optimize oral macrocycle candidates for high-priority immunological targetsTORONTO & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Versant Ventures today announced the launch of Dayra Therapeutics, a startup focused on developing oral macrocyclic peptides for a range of serious diseases. The company has secured more than $70 million in committed funding, including a collaboration with Biogen Inc. that will provide $50 million in upfront capital, as well as an equity commitment from Versant.
Dayra emerged from Versant's Frontier Discovery Engine that spans Toronto and Montreal. Frontier, like the firm's U.S. and European-based Discovery Engines, houses a team of multi-disciplinary scientists working in state-of-the-art laboratory facilities in Canada to enable the launch of novel biotech companies. During the seed stage, Dayra ma...
|
|
|
|
|
|
|
|
|
20.11.25 - 13:33
|
Biogen to Highlight New Lecanemab Data and Scientific Advances at the 18th Clinical Trials on Alzheimer′s Disease Conference (GlobeNewswire EN)
|
|
|
CAMBRIDGE, Mass., Nov. 20, 2025 (GLOBE NEWSWIRE) -- Biogen Inc. (Nasdaq: BIIB) today announced upcoming scientific presentations at the 18th Clinical Trials on Alzheimer's Disease (CTAD) Conference, taking place December 1-4 in San Diego. Data on LEQEMBI® (lecanemab-irmb) will include findings on subcutaneous administration for initiation dosing, the benefits of continued therapy and estimated time savings over 10 years of treatment based on Phase 3 clinical data, and real-world experience from a post-marketing observational study in Japan and the ALZ-NET registry. The company will also share new insights into BIIB080, an investigational antisense oligonucleotide (ASO) therapy, from a healthy-volunteer biodistribution study, as well as research that helps inform understanding of disease progression....
|
|
|
|
|
|
|
17.11.25 - 12:03
|
High Dose Regimen of Nusinersen Receives Positive CHMP Opinion for the Treatment of Spinal Muscular Atrophy (GlobeNewswire EN)
|
|
|
CAMBRIDGE, Mass., Nov. 17, 2025 (GLOBE NEWSWIRE) -- Biogen Inc. (Nasdaq: BIIB) today announced the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) adopted a positive opinion recommending by consensus the approval of the high dose regimen of nusinersen for the treatment of 5q spinal muscular atrophy (SMA). 5q SMA is the most common form of the disease and represents approximately 95% of all SMA cases.3 The CHMP's Positive Opinion will now be reviewed by the European Commission with a final decision expected in January 2026. If adopted by the European Commission, the high dose regimen will be an additional dosing option to the already approved 12 mg low dose regimen....
|
|
Börsentreff auf Facebook |
Börsentreff auf X |
Börsentreff auf Instagram
